Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2018

View Archived Issues

Virpax signs license agreement to use LipoCure's liposome drug delivery technology

Microbiotica and Genentech enter strategic collaboration for IBD

FDA grants rare pediatric disease designation to CLR-131 for the treatment of rhabdomyosarcoma

Intra-Cellular initiates rolling submission of NDA for lumateperone

Moleculin Biotech enters agreement to develop formulation for its STAT3 inhibitor

Alkermes receives payment from Biogen related to BIIB-098 program

Effects on gut microbiome seen with Blautix in irritable bowel syndrome patients

S1P regulation key for bone quality and may constitute a therapeutic target in osteoporosis

Shandong Luoxin Pharmacy Group, Luoxin Biotechnology Shanghai Co. patent BRD4/1/2 inhibitors

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery identify HBV cccDNA inhibitors

New RORC modulators divulged by Bristol-Myers Squibb

Weishang Shanghai Bio-Pharmaceutical discovers mutant EGFR inhibitors

Merck & Co. synthesizes new FXIIa inhibitors

Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL

ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients

First healthy volunteers enrolled in phase I study of BTRX-335140

Positive results presented from ongoing phase I trial of PTI-801 in patients with CF

4D pharma and MSD collaborate to study Keytruda and MRx-0518 combination in solid tumors

FDA grants orphan drug designation to TransCon PTH

EMA grants PRIME designation for dilanubicel

Athersys expands its collaboration with Healios

Phase II results presented for TAK-954 in patients with enteral feeding intolerance

GlaxoSmithKline initiates phase I study of GSK-3858279

Enrollment ongoing in phase III study of pertuzumab and trastuzumab fixed-dose combination

Selinexor liposarcoma trial advances after improvement seen in progression-free survival

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...